Paper23442
Acetohydroxamic acid: clinical studies of a urease inhibitor in patients with staghorn renal calculi.
Griffith DP and 3 others. J Urol, 1978. Cited by 108 papers, by iCite.
Cite this record
ConductScience Library. Acetohydroxamic acid: clinical studies of a urease inhibitor in patients with staghorn renal calculi. Papers, record 23442. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23442
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hydroxamic Acids | Major topic |
| Kidney Calculi | Major topic |
| Urease | Major topic |
| Ammonia | |
| Humans | |
| Hydrogen-Ion Concentration | |
| Hydrolysis | |
| Kinetics | |
| Urea | |
| Urinary Tract Infections |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT07393438 | Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS) | Background |
Source ClinicalTrials.gov
Cited by24
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 108 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42631197 | FDA approved drug containing acetamide group- a mini review. | Front Chem | 2026 | https://conductscience.org/library/papers/42631197 | PubMed |
| 42290516 | Urease inhibitors: current advances, therapeutic potentials, and clinical challenges. | Future Med Chem | 2026 | https://conductscience.org/library/papers/42290516 | PubMed |
| 38681280 | Prognostic Factors for Residual Lithiasis in Patients With Staghorn Calculi Undergoing Percutaneous Nephrolithotomy in the Maya Region of Yucatan, Mexico: A Case-Control Study. | Cureus | 2024 | https://conductscience.org/library/papers/38681280 | PubMed |
| 38516598 | In vitro biological evaluation and in silico studies of linear diarylheptanoids from Curcuma aromatica Salisb. as urease inhibitors. | RSC Med Chem | 2024 | https://conductscience.org/library/papers/38516598 | PubMed |
| 36985670 | Unraveling Binding Mechanism and Stability of Urease Inhibitors: A QM/MM MD Study. | Molecules | 2023 | https://conductscience.org/library/papers/36985670 | PubMed |
| 34062878 | Zerumbone Inhibits Helicobacter pylori Urease Activity. | Molecules | 2021 | https://conductscience.org/library/papers/34062878 | PubMed |
| 33553205 | Encrusted Uropathy: A Comprehensive Overview-To the Bottom of the Crust. | Front Med (Lausanne) | 2020 | https://conductscience.org/library/papers/33553205 | PubMed |
| 33005194 | Urinary Calculi: A Microbiological and Biochemical Analysis at a Tertiary Care Hospital in Eastern Nepal. | Int J Microbiol | 2020 | https://conductscience.org/library/papers/33005194 | PubMed |
| 32719668 | Alternative Therapeutic Options to Antibiotics for the Treatment of Urinary Tract Infections. | Front Microbiol | 2020 | https://conductscience.org/library/papers/32719668 | PubMed |
| 32257805 | Metabolic evaluation and medical management of staghorn calculi. | Asian J Urol | 2020 | https://conductscience.org/library/papers/32257805 | PubMed |
| 24497689 | Standardizing the reporting of percutaneous nephrolithotomy complications. | Indian J Urol | 2014 | https://conductscience.org/library/papers/24497689 | PubMed |
| 20449779 | [Urinary tract infections and Urolithiasis]. | Urologe A | 2010 | https://conductscience.org/library/papers/20449779 | PubMed |
| 17848149 | Using verapamil as protective factor in renal ischemia reperfusion injury during anatrophic nephrolithotomy. | Bosn J Basic Med Sci | 2007 | https://conductscience.org/library/papers/17848149 | PubMed |
| 15614579 | Encrustation of biomaterials in the urinary tract. | Urol Res | 2005 | https://conductscience.org/library/papers/15614579 | PubMed |
| 6737406 | Bacteriological and crystallographical analysis of urinary calculi: aid to patient management. | J R Soc Med | 1984 | https://conductscience.org/library/papers/6737406 | PubMed |
| 6480281 | Applicability of biosuppressin as an urease-inhibitor. | Int Urol Nephrol | 1984 | https://conductscience.org/library/papers/6480281 | PubMed |
| 6401560 | Prospects for prevention. | Br Med J (Clin Res Ed) | 1983 | https://conductscience.org/library/papers/6401560 | PubMed |
| 6119364 | Urinary tract infection. | J R Coll Physicians Lond | 1981 | https://conductscience.org/library/papers/6119364 | PubMed |
| 3928387 | Pharmacokinetics of acetohydroxamic acid in patients with staghorn renal calculi. | Eur J Clin Pharmacol | 1985 | https://conductscience.org/library/papers/3928387 | PubMed |
| 3771124 | S.E.M. study of urease-induced crystalluria in the presence of hydroxamic derivatives. | Int Urol Nephrol | 1986 | https://conductscience.org/library/papers/3771124 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/23442
GET https://conductscience.org/api/papers/v1/23442/cited_by?page=2